骨膜蛋白在慢性阻塞性肺疾病中的研究进展
Research Progress of Periostin in Chronic Obstructive Pulmonary Disease
DOI: 10.12677/acm.2025.1582245, PDF,   
作者: 周佳佳:吉首大学医学院,湖南 吉首;吴秀明*:张家界市人民医院呼吸与危重症医学科,湖南 张家界
关键词: 慢性阻塞性肺疾病骨膜蛋白Chronic Obstructive Pulmonary Disease Periostin
摘要: 慢性阻塞性肺病(COPD)是一种以慢性气道炎症反应为病理基础的临床常见呼吸系统疾病,慢阻肺可防可控,其典型的临床特点是持久的呼吸道症状及进行性的气流受限。骨膜蛋白属于细胞外基质的重要组成部分,在组织形成、纤维化进程等方面都起到了非常关键的作用。最新的研究显示,它在COPD的炎症反应、气道重塑、肺血管重塑以及肺泡结构破坏等病理过程中起到重要作用,与COPD的病情进展、肺功能损害程度变化、急性加重、并发肺动脉高压等相关联,以骨膜蛋白为靶点的COPD治疗方法具有一定的临床前景。本综述汇总近年来的研究成果,对骨膜蛋白在COPD中的相关作用进行综述。
Abstract: Chronic obstructive pulmonary disease (COPD) is a common clinical respiratory disease based on chronic airway inflammatory responses. COPD is preventable and controllable, and its typical clinical characteristics are persistent respiratory symptoms and progressive airflow limitation. Periostin is an important component of the extracellular matrix and plays a very crucial role in tissue formation, the process of fibrosis, etc. The latest research shows that it plays an important role in pathological processes such as inflammatory response, airway remodeling, pulmonary vascular remodeling and alveolar structure destruction in COPD. It is associated with the progression of COPD, changes in the degree of lung function impairment, acute exacerbation, and concurrent pulmonary hypertension. The COPD treatment method targeting periostin has certain clinical prospects. This review summarizes the research results in recent years and reviews the related role of periostin in COPD.
文章引用:周佳佳, 吴秀明. 骨膜蛋白在慢性阻塞性肺疾病中的研究进展[J]. 临床医学进展, 2025, 15(8): 382-389. https://doi.org/10.12677/acm.2025.1582245

参考文献

[1] Wang, Z., An, J., Zhu, D., Chen, H., Lin, A., Kang, J., et al. (2022) Periostin: An Emerging Activator of Multiple Signaling Pathways. Journal of Cell Communication and Signaling, 16, 515-530. [Google Scholar] [CrossRef] [PubMed]
[2] 曾峰, 黄建芬, 余新林, 等. 骨膜蛋白的研究新进展[J]. 中国医学创新, 2021, 18(7): 171-176.
[3] Nikoloudaki, G., Creber, K. and Hamilton, D.W. (2020) Wound Healing and Fibrosis: A Contrasting Role for Periostin in Skin and the Oral Mucosa. American Journal of Physiology-Cell Physiology, 318, C1065-C1077. [Google Scholar] [CrossRef] [PubMed]
[4] Wishman, M.D., Sgrignoli, W.M., Patterson, B.M., Nepola, J.V., Wolf, B.R., Bozoghlian, M., et al. (2025) A Review of Periostin in Orthopedics. Osteoarthritis and Cartilage Open, 7, Article ID: 100600. [Google Scholar] [CrossRef] [PubMed]
[5] Dorafshan, S., Razmi, M., Safaei, S., Gentilin, E., Madjd, Z. and Ghods, R. (2022) Periostin: Biology and Function in Cancer. Cancer Cell International, 22, Article No. 315. [Google Scholar] [CrossRef] [PubMed]
[6] Sonnenberg-Riethmacher, E., Miehe, M. and Riethmacher, D. (2021) Periostin in Allergy and Inflammation. Frontiers in Immunology, 12, Article 722170. [Google Scholar] [CrossRef] [PubMed]
[7] Ono, J., Takai, M., Kamei, A., Azuma, Y. and Izuhara, K. (2021) Pathological Roles and Clinical Usefulness of Periostin in Type 2 Inflammation and Pulmonary Fibrosis. Biomolecules, 11, Article 1084. [Google Scholar] [CrossRef] [PubMed]
[8] Nagata, M., Nakagome, K. and Soma, T. (2020) Mechanisms of Eosinophilic Inflammation. Asia Pacific Allergy, 10, e14. [Google Scholar] [CrossRef] [PubMed]
[9] Oishi, K., Matsunaga, K., Shirai, T., Hirai, K. and Gon, Y. (2020) Role of Type 2 Inflammatory Biomarkers in Chronic Obstructive Pulmonary Disease. Journal of Clinical Medicine, 9, 2670. [Google Scholar] [CrossRef] [PubMed]
[10] Alzobaidi, N., Rehman, S., Naqvi, M., Gulati, K. and Ray, A. (2022) Periostin: A Potential Biomarker and Therapeutic Target in Pulmonary Diseases. Journal of Pharmacy & Pharmaceutical Sciences, 25, 137-148. [Google Scholar] [CrossRef] [PubMed]
[11] Iype, J. and Fux, M. (2021) Basophils Orchestrating Eosinophils’ Chemotaxis and Function in Allergic Inflammation. Cells, 10, Article 895. [Google Scholar] [CrossRef] [PubMed]
[12] Janssen-Heininger, Y., Reynaert, N.L., van der Vliet, A. and Anathy, V. (2020) Endoplasmic Reticulum Stress and Glutathione Therapeutics in Chronic Lung Diseases. Redox Biology, 33, Article ID: 101516. [Google Scholar] [CrossRef] [PubMed]
[13] 王心晓, 齐见旭, 冯书. 肺癌合并支气管哮喘患者白细胞介素-13和骨膜蛋白表达水平与气道重塑严重程度的相关性分析[J]. 中国中西医结合急救杂志, 2021, 28(1): 35-38.
[14] 张毛为, 陈碧, 孙宜田, 等. 慢性阻塞性肺疾病患者体内骨膜蛋白的表达及其意义[J]. 中国校医, 2021, 35(12): 940-942, 945.
[15] Golpe, R., Martín-Robles, I., Sanjuán-López, P., Pérez-De-Llano, L., González-Juanatey, C., López-Campos, J.L., et al. (2017) Differences in Systemic Inflammation between Cigarette and Biomass Smoke-Induced COPD. International Journal of Chronic Obstructive Pulmonary Disease, 12, 2639-2646. [Google Scholar] [CrossRef
[16] Carpaij, O.A., Muntinghe, F.O.W., Wagenaar, M.B., Habing, J.W., Timens, W., Kerstjens, H.A.M., et al. (2018) Serum Periostin Does Not Reflect Type 2-Driven Inflammation in COPD. Respiratory Research, 19, Article No. 112. [Google Scholar] [CrossRef] [PubMed]
[17] Nejman-Gryz, P., Górska, K., Paplińska-Goryca, M., Proboszcz, M. and Krenke, R. (2020) Periostin and Thymic Stro-mal Lymphopoietin—Potential Crosstalk in Obstructive Airway Diseases. Journal of Clinical Medicine, 9, Article 3667. [Google Scholar] [CrossRef] [PubMed]
[18] 董媛, 朱述阳, 卞宏, 等. 骨膜蛋白在慢性阻塞性肺病急性加重期的表达及诊断意义[J]. 中国现代医学杂志, 2018, 28(29): 94-98.
[19] 余长芳, 余海霞, 谭裕尧, 等. 血清NGAL、VEGFA、Periostin水平与哮喘——慢性阻塞性肺疾病重叠综合征患者肺功能的关系[J]. 广西医科大学学报, 2021, 38(8): 1546-1551.
[20] 张涛, 王卓. 不同类型COPD急性加重期患者血浆periostin、TNF-α、ET-1水平变化及其意义[J]. 贵州医药, 2022, 46(8): 1211-1212.
[21] Matsusaka, M., Kabata, H., Fukunaga, K., Suzuki, Y., Masaki, K., Mochimaru, T., et al. (2015) Phenotype of Asthma Related with High Serum Periostin Levels. Allergology International, 64, 175-180. [Google Scholar] [CrossRef] [PubMed]
[22] Park, H.Y., Lee, H., Koh, W., Kim, S., Jeong, I.A., Koo, H., et al. (2015) Association of Blood Eosinophils and Plasma Periostin with FEV1 Response after 3-Month Inhaled Corticosteroid and Long-Acting β2-Agonist Treatment in Stable COPD Patients. International Journal of Chronic Obstructive Pulmonary Disease, 11, 23-30. [Google Scholar] [CrossRef] [PubMed]
[23] 黄挺. 血清骨膜蛋白在重度AECOPD并发营养不良患者的表达[D]: [硕士学位论文]. 百色: 右江民族医学院, 2024.
[24] Konstantelou, E., Papaioannou, A.I., Loukides, S., Bartziokas, K., Papaporfyriou, A., Papatheodorou, G., et al. (2017) Serum Periostin in Patients Hospitalized for COPD Exacerbations. Cytokine, 93, 51-56. [Google Scholar] [CrossRef] [PubMed]
[25] Johnson, S., Sommer, N., Cox-Flaherty, K., Weissmann, N., Ventetuolo, C.E. and Maron, B.A. (2023) Pulmonary Hypertension: A Contemporary Review. American Journal of Respiratory and Critical Care Medicine, 208, 528-548. [Google Scholar] [CrossRef] [PubMed]
[26] 赵欣, 韦清霞, 杨隽. 骨形态形成蛋白信号在内皮生理及肺动脉高压中的调控机制[J]. 协和医学杂志, 2020, 11(6): 720-726.
[27] Nie, X., Shen, C., Tan, J., Wu, Z., Wang, W., Chen, Y., et al. (2020) Periostin: A Potential Therapeutic Target for Pulmonary Hypertension? Circulation Research, 127, 1138-1152. [Google Scholar] [CrossRef] [PubMed]
[28] Bousseau, S., Sobrano Fais, R., Gu, S., Frump, A. and Lahm, T. (2023) Pathophysiology and New Advances in Pulmonary Hypertension. BMJ Medicine, 2, e000137. [Google Scholar] [CrossRef] [PubMed]
[29] Yoshida, T., Nagaoka, T., Nagata, Y., Suzuki, Y., Tsutsumi, T., Kuriyama, S., et al. (2022) Periostin‐Related Progression of Different Types of Experimental Pulmonary Hypertension: A Role for M2 Macrophage and FGF‐2 Signalling. Respirology, 27, 529-538. [Google Scholar] [CrossRef] [PubMed]
[30] Nakagome, K. and Nagata, M. (2024) The Possible Roles of IL-4/IL-13 in the Development of Eosinophil-Predominant Severe Asthma. Biomolecules, 14, Article 546. [Google Scholar] [CrossRef] [PubMed]
[31] 陈典, 隆寰宇, 张丛溪, 等. 2025年GOLD慢性阻塞性肺疾病诊断、治疗、管理及预防全球策略更新要点解读[J]. 中国全科医学, 2025, 28(16): 1937-1949.